New triple combo aims to tackle Hard-to-Treat liver cancer

NCT ID NCT07537777

Not yet recruiting Disease control Sponsor: Nanfang Hospital, Southern Medical University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a combination of two drugs (Benmelstobart and Anlotinib) plus targeted radiation (SBRT) in 29 adults with liver cancer that has spread to a few other spots and no longer responds to first-line treatment. The goal is to see if this triple therapy can slow cancer growth and improve survival. Participants will receive treatment for up to 2 years, with close monitoring for side effects and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Benmelstobart (an immunotherapy drug), Anlotinib (a targeted therapy drug), and SBRT (a precise type of radiation therapy)
What this could lead to: If this combination works, it could offer a new treatment option for people with advanced liver cancer that has spread and stopped responding to initial therapy.
What could go wrong: This is a small, early-phase trial with only 29 participants and no comparison group, so results may not apply broadly. The combination of drugs and radiation may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANLOTINIB are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Balkan nephropathy BNAR syndrome hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANLOTINIB BENMELSTOBART FIRST-LINE TARGETED THERAPY FAILURE HEPATOCELLULAR CARCINOMA (HCC) OLIGOMETASTATIC HEPATOCELLULAR CARCINOMA SBRT

Contacts and locations

Locations

Nanfang Hospital of Southern Medical University

Guangzhou, Guangdong, 510515, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.